title: Inhibitory effect of human breast cancer cell proliferation via p21-mediated G1 cell cycle arrest by araliadiol isolated from Aralia cordata Thunb.
abstract: A new polyacetylenic compound, araliadiol, was isolated from the leaves of Aralia cordata Thunb. (Araliaceae). The structure of araliadiol was determined to be 3( S),8( R)-pentadeca-1,9( Z)-diene-4,6-diyne-3,8-diol by MS, NMR, IR, and UV spectroscopic analysis as well as Mosher ester reaction. Araliadiol displayed a significant inhibitory effect on the growth of a human breast adenocarcinoma cell line (MCF-7), with an IC (50) value for cytotoxicity of 6.41 µg/mL. Cell cycle analysis revealed that the proportion of cells in the G (1) phase of the cell cycle increased in a dose-dependent manner (from 54.7 % to 72.0 %) after 48 h exposure to araliadiol at dosages ranging from 0 to 80 µM. The results suggest that araliadiol inhibits cell cycle progression of MCF-7 at the G (1)-S transition. After treatment with araliadiol, phosphorylation of retinoblastoma protein (Rb) in MCF-7 cells was inhibited, accompanied by a decrease in the levels of cyclin D (3) and cyclin-dependent kinase 4 (cdk4) and an increase in the expression of p21 (WAF-1/Cip1). However, the expression of phosphorylated p53 (Ser15) and Chk2 was not altered in MCF-7 cells. These findings indicate that araliadiol exhibits its growth-inhibitory effects on MCF-7 cells through downregulation of cdk4 and cyclin D (3), and upregulation of p21 (WAF-1/Cip1) by a p53-independent mechanism.
authors: Department of Forestry, National Chung-Hsing University, Taichung, Taiwan.
authors: Wen-Ling
authors: WL
authors: Cheng
authors: Ting-Yu
authors: TY
authors: Lin
authors: Yen-Hsueh
authors: YH
authors: Tseng
authors: Fang-Hua
authors: FH
authors: Chu
authors: Pin-Ju
authors: PJ
authors: Chueh
authors: Yueh-Hsiung
authors: YH
authors: Kuo
authors: Sheng-Yang
authors: SY
authors: Wang
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000517:prevention & control; D027983:Aralia / Q000737:chemistry*; D001943:Breast Neoplasms / Q000473:pathology / Q000517:prevention & control; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000187:drug effects / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D016193:G1 Phase / Q000187:drug effects; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D018515:Plant Leaves / Q000737:chemistry; D053279:Polyynes / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D016196:S Phase / Q000187:drug effects
chemical_list: C558256:3(S),8(R)-pentadeca-1,9(Z)-diene-4,6-diyne-3,8-diol; D018797:Cell Cycle Proteins; D050759:Cyclin-Dependent Kinase Inhibitor p21; D006131:Growth Inhibitors; D053279:Polyynes